Severity assessment in community-acquired pneumonia: A review

QJM: An International Journal of Medicine

Volumn 102, Issue 6, 2009, Pages 379-388

  Singanayagam, Aran ^a   Chalmers, J D ^a   Hill, A T ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; MEDICAL DECISION MAKING; MORTALITY; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM;

EID: 67749106168     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp027     Document Type: Review

References (60)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281 61-6.
2. MacFarlane JT, Boldy JT. Update of BTS pneumonia guidelines: What's new? Thorax 2004; 59:364-6.
3. American Thoracic Society. Guidelines for the Management of Adults with Community Acquired Pneumonia, Diagnosis, Assessment of Severity, Antimicrobial Therapy and Prevention. Am J Respir Crit Care Med 2001; 163:1730-54
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Disease Society of American/American Thoracic Society Consensus Guidelines for the Management of Community Acquired Pneumonia in Adults. Clin Infect Dis 2007; 44:S27-72.
5. Neill AM, Martin IR, Weir R, Anderson R, Chereshky A, Epton MJ, et al Community-acquired pneumonia: Aetiology and usefulness of severity criteria on admission. Thorax 1996; 51:1010-16.
6. Tang CM, Macfarlane JT. Early management of younger adults dying of community-acquired pneumonia. Respir Med 1993; 87:289-94.
7. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community- acquired pneumonia. N Engl J Med 1997; 336:243-50.
8. Man SY, Lee N, Ip M, Antonio GE, Chau SS, Mak P, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007; 62 348-53.
9. Buising KL, Thursky KA, Black JF, MacGregorL, Street AC, Kennedy MP, et al. A prospective comparison of severity scores for identifying patients with severe communityacquired pneumonia: Reconsidering what is meant by severe pneumonia. Thorax 2006; 61:419-24.
10. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121:219-25.
11. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, et al Prospective comparison of three validated prediction rules for prognosis in community acquired pneumonia. Am J Med 2005; 118 384-92.
12. Angus DC, Marrie T, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: Use of intensive care services and evaluation of the American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002; 166 717-23.
13. Lim WS, van der Erden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community-acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003; 58:377-82.
14. Barlow GD, Nathwani D, Davey PG. The CURB65 pneumonia severity score outperforms generic sepsis scores and early warning in predicting mortality in community acquired pneumonia. Thorax 2007; 62 253-9.
15. Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community-acquired pneumonia. Thorax 2008; 63:698-702.
16. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260 93-101.
17. Bont J, Hak E, Hoes AW, MacFarlane JT, Verheij TJ. Predicting death in elderly patients with community-acquired pneumonia: A prospective validation study reevaluating the CRB65 severity assessment tool. Arch Intern Med 2008; 168:1465-8.
18. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Imaizumi K, et al Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology 2008; 13:731-5.
19. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, et al. Identifying severe communityacquired pneumonia in the emergency department: A simple clinical prediction tool. Emerg Med Australas 2007; 19:418-26.
20. Espana PP, Capestelagui, Gorodo I, Esteban C, Oribe M, Ortega M, et al. Development and validation of a clinical prediction for severe community-acquired pneumonia. Am J Respir Crit Care 2006; 174 1249-56.
21. Marrie TJ, Fine MJ, Kapoor WN, Coley CM, Singer DE, Obrosky DS. Community-acquired pneumonia and do not resuscitate orders. J Am Geriatr Soc 2002; 50:290-9.
22. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DJ, Kapoor WN, et al. Causes of death for patients with community acquired pneumonia: Results from the pneumonia patient outcomes research team cohort study. Arch Intern Med 2002; 162:1059-64.
23. Mortensen EM, Kapoor WN, Chang CC, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37:1612-24.
24. Ewig S, de Roux A, Garcia E, Mensa J, Niederman M, Torres A. Validation of predictive rules and indices of severity for community-acquired pneumonia. Thorax 2004; 59:421-7.
25. Valencia M, Badia JR, Calvacanti M, Ferrer M, Agusti C, Angrill J, et al. Pneumonia severity index class V patients with community-acquired pneumonia: Characteristics, outcomes and value of severity scores. Chest 2007; 132:515-22.
26. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al SMART-COP: A tool for predicting the need for intensive respiratory or vasopressor support in communityacquired pneumonia. Clin Infect Dis 2008; 47:375-84.
27. Cham CW, Haq SM, Rahamim J. Empyema Thoracis: A problem with late referral. Thorax 1993; 48:925-7.
28. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfield LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275:134-41.
29. LeMense GP, Strange C, Sahn SA. Empyema Thoracis: Therapeutic management and outcome. Chest 1995; 107:1532-7.
30. Alfagame I, Munoz F, Pena N, Umbria S. Empyema of the thorax in adults: etiology, microbiologic findings and management. Chest 1993; 103:839-43.
31. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT. Hospitalized communityacquired pneumonia in elderly: age- and sex-related patterns of care and outcome in the United states. Am J Respir Crit Care Med 2002; 165:766-72.
32. American college of Chest physicians/Society of Critical Care medicine consensus conference: Definitions for sepsis and guidelines for use of innovative therapies in sepsis. Crit Care Med 1992; 20 864-74.
33. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-23.
34. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE - acute physiology and chronic health evaluation: A physiologically based classification system. Crit Care Med 1981; 9:591-7.
35. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-29.
36. Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early warning score in medical admissions. QJM 2001; 94 521-6.
37. Lim WS. Severity assessment in community-acquired pneumonia: Moving on. Thorax 2007; 62:287-8.
38. Woodhead M. Assessment of illness severity in community acquired pneumonia: A useful new prediction tool? Thorax 2003; 58 371-2.
39. Barlow G, Nathwani D, Myers E, Sullivan F, Stevens N, Duffy R, et al Identifying barriers to the rapid administration of appropriate antibiotics in community acquired pneumonia. J Antimicrob Chemother 2008; 61:442-51.
40. Collini P, Beadsworth M, Anson J, Neal T, Burnham P, Deegan P, et al Community-acquired pneumonia: Doctors do not follow national guidelines. Postgrad Med J 2007; 83:552-5.
41. Tsiouto AG, Sakorafas GH, Anagnostopoulos G, Bramis J. Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit 2005; 11:RA76-85.
42. Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community acquired pneumonia: When does it happen and do systemic inflammatory response syndrome criteria help predict course? Chest 2006; 129: 968-78.
43. Kollef KE, Reichley RM, Micek ST, Kollef MH. The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30 day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest 2008; 133:363-9.
44. Spindler C, Ortqvist A. Prognostic score systems and community-acquired bacteraemia pneumococcal pneumonia. Eur Respir J 2006; 28 816-23.
45. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community acquired pneumonia. Eur Respir J 2008; 32:726-32.
46. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-Reactive protein: A clinical marker in community-acquired pneumonia. Chest 1995; 108:1288-91.
47. Coelho L, Povoa P, Almeida E, Fernandes A, Mealha R, Moreira P, et al Usefulness of C-reactive protein in monitoring severe community-acquired pneumonia clinical course. Crit Care 2007; 11:R92.
48. Garcia Vazquez E, Martinez JA, Mensa J, Sanchez F, Marcos MA, de Roux A, et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003; 21:702-5.
49. Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, et al. Markers of treatment failure in community-acquired pneumonia. Thorax 2008; 63:447-52.
50. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomised trial. Am J Respir Crit Care 2006; 174:84-93.
51. Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, et al. on behalf of the CAPNETZ study group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31:349-55.
52. Masiá M, Gutiérrez F, Shum C, Padilla S, Navarro JC, Flores E, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005; 128:2223-9.
53. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, et al Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003; 21:939-43.
54. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care 2006; 10 R96.
55. Kruger S, Papassotiriou J, Marre R, Richter K, Schumann C, von Baum H, et al. CAPNETZ Study Group. Pro-atrial natriuetic peptide and provasopression to predict severity and prognosis in community-acquired pneumonia: Results form the German competence network CAPNETZ. Intensive Care Med 2007; 33:2069-78.
56. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker in lower respiratory tract infections. Eur J Clin Invest 2007; 37 145-52.
57. Arnold FW, Ramirez JA, McDonald LC, Xia EL. Pneumonia severity index vs clinical judgement. Chest 2003; 124:121-4.
58. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott-Watson R, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in elderly: age- and sex-related patterns of care and outcome in the United states. Am J Respir Crit Care Med 2002; 165:766-72.
59. Chalmers JC, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support in young adults admitted with community acquired pneumonia. Clin Infect Dis 2008; 47 1571-4.
60. McCartney C, Cookson B, Dance D, Day C, Duerden B, Elston T, et al. Interim Guidance on Diagnosis and Management of Panton-Valentine Leukocidin-associated Staphyloccal Infections in the UK. London, Department of Health, 2006.